Shares of NxStage Medical Inc. (NASDAQ:NXTM) traded down 1.8% during mid-day trading on Friday . The company traded as low as $21.92 and last traded at $22.11, with a volume of 123,346 shares traded. The stock had previously closed at $22.52.

A number of equities analysts recently commented on the stock. Wells Fargo & Co. reiterated a “sell” rating on shares of NxStage Medical in a research report on Thursday, May 5th. Canaccord Genuity reiterated a “buy” rating on shares of NxStage Medical in a research report on Wednesday, May 4th. Zacks Investment Research upgraded shares of NxStage Medical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Piper Jaffray Cos. reiterated a “buy” rating and issued a $21.00 target price on shares of NxStage Medical in a research report on Friday, June 3rd. Finally, Northland Securities upgraded shares of NxStage Medical from a “market perform” rating to an “outperform” rating and set a $25.00 target price on the stock in a research report on Tuesday, June 28th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. NxStage Medical currently has a consensus rating of “Buy” and an average price target of $24.50.

The firm’s market cap is $1.43 billion. The company has a 50-day moving average price of $20.99 and a 200 day moving average price of $17.80.

NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings data on Wednesday, May 4th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.03. During the same period last year, the company earned ($0.09) earnings per share. The firm earned $89.20 million during the quarter, compared to analysts’ expectations of $88.40 million. The business’s revenue for the quarter was up 12.2% on a year-over-year basis. On average, equities analysts forecast that NxStage Medical Inc. will post ($0.12) earnings per share for the current year.

In other news, President Joseph E. Turk, Jr. sold 1,500 shares of the stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $17.89, for a total value of $26,835.00. Following the completion of the sale, the president now directly owns 103,280 shares of the company’s stock, valued at $1,847,679.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Several hedge funds have recently made changes to their positions in NXTM. Jennison Associates boosted its stake in shares of NxStage Medical by 12.0% in the third quarter. Jennison Associates now owns 1,049,780 shares of the medical device company’s stock worth $16,555,000 after buying an additional 112,792 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in shares of NxStage Medical by 9.0% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 53,686 shares of the medical device company’s stock worth $1,176,000 after buying an additional 4,450 shares during the period. California State Teachers Retirement System boosted its stake in shares of NxStage Medical by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 117,165 shares of the medical device company’s stock worth $2,567,000 after buying an additional 1,869 shares during the period. Rhumbline Advisers boosted its stake in shares of NxStage Medical by 8.3% in the fourth quarter. Rhumbline Advisers now owns 68,426 shares of the medical device company’s stock worth $1,499,000 after buying an additional 5,240 shares during the period. Finally, New York State Common Retirement Fund boosted its stake in shares of NxStage Medical by 4.1% in the fourth quarter. New York State Common Retirement Fund now owns 76,493 shares of the medical device company’s stock worth $1,676,000 after buying an additional 3,000 shares during the period.

NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.